John Puisis, president and CEO of Third Wave Technologies resigned from the company late last week. According to documents filed with the Securities Exchange Commission, Puisis received a severance package that includes $880,000, of which $220,000 has been paid, and the remainder will be paid in 18 monthly installments. Puisis will also receive $33,572 in cash, to be paid in 12 monthly installments, and immediate vesting of any unvested stock options that he'd received. Puisis will collect a maximum of $15,000 in outplacement consulting services.
GE Healthcare veteran Kevin Conroy, currently Third Wave's vice president and general counsel, replaced Puisis.
GE Healthcare named Gene Cartwright as president of its Molecular Diagnostics business to lead the development of the in-vitro clinical diagnostics business based in Piscataway, NJ. Cartwright previously worked at Abbott Laboratories as vice-president of strategic programs for its molecular diagnostics business. He received his PhD in chemistry from Stanford University.
Orchid Cellmark named Gordon J. Brown to fill the newly created position of senior vice-president of global laboratory operations, the company said today. The appointment is effective Jan. 1, 2006. Brown most recently served as a vice-president and general manager of Esoterix, a subsidiary of Laboratory Corporation of America. Before moving to Esoterix in 2004, he was program director of front-end operations, director of integration and director of logistics at Quest Diagnostics. From 1987 to 1995, he held various production planning and manufacturing positions at American Home Products, now Wyeth. Brown has a BS in business logistics from Pennsylvania State University and a MBA in finance from Fordham University.
Markus Böhm has left his position as international product manager of microarray solutions at Schott-Nexterion, Böhm said this week.
He will begin working for Illumina in January 2006 and will be responsible for the San Diego-based array company's accounts in Germany, Austria, and Switzerland.
Böhm said that Alistair Rees has taken his position at Schott.
Affymetrix this week launched standard and custom SNP panels for targeted genotyping applications.
The panels span 1,500 to 20,000 SNPs per assay, and include 20K cSNP, 10K cSNP, and 3K Mapping by Admixture Linkage Disequilibrium for whole-genome association analysis studies. There is also a 9K Immune-Inflammation Panel for disease-related candidate gene studies. And there are 10K Bovine, 5K Mouse, and 5K Rat panels for common animal research.
The panels use the molecular inversion probe assay technology employed by ParAllele BioScience in its MegAllele assay. The assays are the first MIP products to be released since Affy acquired ParAllele in October.
Affymetrix also released its GeneChip Human Mitochondrial Resequencing Array 2.0, which the firm claims enables researchers to analyze the entire sequence of the mitochondrial genome in a single 48 hour experiment. Affy said the Mitochondrial Array interrogates 16,500 bases of the human mitochondrial genome using only three PCR reactions. The company added that the method could be used for detecting variants associated with genetic disease, forensics, population studies, or stem cells.
NOTE: This is the last issue of Pharmacogenomics Reporter to be
published in 2005. We will resume our
normal publishing schedule on Jan. 5, 2006.